Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia (B-CLL): Comparison of indolent and progressive disease

Medical Oncology

Volumn 22, Issue 3, 2005, Pages 291-302

  Kiaii, Shahryar ^a   Choudhury, Aniruddha ^a   Mozaffari, Fariba ^a   Kimby, Eva ^a   Österborg, Anders ^a   Mellstedt, Håkan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

B CLL; Indolent; Progressive; Signaling; T cell

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 4; PROTEIN KINASE ZAP 70; PROTEIN P56;

ADULT; AGED; ARTICLE; B CELL LEUKEMIA; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE;

AGED; AGED, 80 AND OVER; ANTIGENS, CD; CYTOKINES; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKEMIA, B-CELL, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; T-LYMPHOCYTES;

EID: 23844436988     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:22:3:291     Document Type: Article

References (44)

1. Kipps TJ. Chronic lymphocytic leukemia. Curr Opin Hematol 2000;7(4):223-234.
2. Scrivener S, Goddard RV, Kaminski ER, Prentice AG. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 2003;44(3):383-389.
3. Mellstedt H, Pettersson D. Lymphocyte subpopulations in chronic lymphocytic leukemia. Characterization by cell surface markers, cytotoxic activity, and mitogenic stimulation. Scand J Immunol 1974;3(3):303-310.
4. Mellstedt H, Pettersson D, Holm G. Lymphocyte subpopulations in chronic lymphocytic leukemia (CLL). Relation to the activity of the disease. Acta Med Scand 1978;204(6):485-489.
5. Callery RT, et al. Functional abnormalities associated with T lymphocytes from patients with chronic lymphocytic leukemia. Clin Immunol Immunopathol 1980;17(3):451-458.
6. Kimby E, Mellstedt H, Nilsson B, Bjorkholm M, Holm G. Differences in blood T and NK cell populations between chronic lymphocytic leukemia of B cell type (B-CLL) and monoclonal B-lymphocytosis of undetermined significance (B-MLUS). Leukemia 1989;3(7):501-504.
7. Briggs PG, Kraft N, Atkins RC. T cells and CD45R expression in B-chronic lymphocytic leukemia. Leuk Res 1990;14(2):155-159.
8. Catovsky D, Miliani E, Okos A, Galton DA. Clinical significance of T-cells in chronic lymphocytic leukaemia. Lancet 1974;2(7883):751-752.
9. Semenzato G, Pezzutto A, Foa R, Lauria F, Raimondi R. T lymphocytes in B-cell chronic lymphocytic leukemia: characterization by monoclonal antibodies and correlation with Fc receptors. Clin Immunol Immunopathol 1983;26(2):155-161.
10. Herrmann F, Lochner A, Philippen H, Jauer B, Ruhl H. Imbalance of T cell subpopulations in patients with chronic lymphocytic leukaemia of the B cell type. Clin Exp Immunol 1982;49(1):157-162.
11. Kay NE, Johnson JD, Stanek R, Douglas SD. T-cell subpopulations in chronic lymphocytic leukemia: abnormalities in distribtuion and in in vitro receptor maturation. Blood 1979;54(2):540-544.
12. Totterman TH, Carlsson M, Simonsson B, Bengtsson M, Nilsson K. T-cell activation and subset patterns are altered in B-CLL and correlate with the stage of the disease. Blood 1989;74(2):786-792.
13. Bartik MM, Welker D, Kay NE. Impairments in immune cell function in B cell chronic lymphocytic leukemia. Semin Oncol 1998;25(1):27-33.
14. Kay NE. Abnormal T-cell subpopulation function in CLL: excessive suppressor (T gamma) and deficient helper (T mu) activity with respect to B-cell proliferation. Blood 1981;57(3):418-420.
15. Kay NE, Perri RT. Immunobiology of malignant B cells and immunoregulatory cells in B-chronic lymphocytic leukemia. Clin Lab Med 1988;8(1):163-177.
16. Zaknoen SL, Kay NE. Immunoregulatory cell dysfunction in chronic B-cell leukemias. Blood Rev 1990;4(3):165-174.
17. Epstein LB, Cline MJ. Chronic lymphocytic leukaemia. Studies on mitogen-stimulated lymphocyte interferon as a new technique for assessing T lymphocyte effector function. Clin Exp Immunol 1974;16(4):553-563.
18. Hill SJ, Peters SH, Ayliffe MJ, Merceica J, Bansal AS. Reduced IL-4 and interferon-gamma (IFN-gamma) expression by CD4 T cells in patients with chronic lymphocytic leukaemia. Clin Exp Immunol 1999;117(1):8-11.
19. Scrivener S, Prentice AG, Kaminski ER, Demaine A. Activation and interaction markers and cytokine production are dysfunctional in T-cells from B-cell chronic lymphocytic leukemia patints. Leuk Lymphoma 2001b:42:S1:36.
20. Walunas TL, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994;1(5):405-413.
21. Grewal IS, Flavell RA. The CD40 ligand. At the center of the immune universe? Immunol Res 1997;16(1):59-70.
22. Mu X, Kay NE, Gosland MP, Jennings CD. Analysis of blood T-cell cytokine expression in B-chronic lymphocytic leukaemia: evidence for increased levels of cytoplasmic IL-4 in resting and activated CD8 T cells. Br J Haematol 1997;96(4):733-735.
23. Lundin J, et al. Interleukin 4 therapy for patients with chronic lymphocytic leukaemia: a phase I/II study. Br J Haematol 2001;112(1):155-160.
24. Luo HY, Rubio M, Biron G, Delespesse G, Sarfati M. Antiproliferative effect of interleukin-4 in B chronic lymphocytic leukemia. J Immunother 1991;10(6):418-425.
25. van Kooten C, Rensink I, Aarden L, van Oers R. Interleukin-4 inhibits both paracrine and autocrine tumor necrosis factor-alpha-induced proliferation of B chronic lymphocytic leukemia cells. Blood 1992;80(5):1299-1306.
26. Buschle M, et al. Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J Exp Med 1993;177(1):213-218.
27. Panayiotidis P, Ganeshaguru K, Jabbar SA, Hoffbrand AV. Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukaemia cells in vitro. Br J Haematol 1993;85(3):439-445.
28. Mainou-Fowler T, Craig VA, Copplestone AJ, Hamon MD, Prentice AG. Effect of anti-APO1 on spontaneous apoptosis of B cells in chronic lymphocytic leukaemia: the role of bcl-2 and interleukin 4. Leuk Lymphoma 1995;19(3-4):301-308.
29. Jewell AP, et al. Cytokine induction of leucocyte adhesion molecule-1 (LAM- 1) expression on chronic lymphocytic leukaemia cells. Leukemia 1992;6(5):400-404.
30. Acuto O, Cantrell D. T cell activation and the cytoskeleton. Annu Rev Immunol 2000;18:165-184.
31. Goldsby RA, Kindt TJ, Kuby J, Osborne BA. Kuby Immunology. 4th ed. W.H. Freeman: New York, 2000.
32. Johnson AJ, Mone AP, Abhyankar V, Byrd JC. Advances in the therapy of chronic lymphocytic leukemia. Curr Opin Hematol 2003;10(4):297-305.
33. Pekarsky Y, et al. Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proc Natl Acad Sci USA 2000;97(7):3028-3033.
34. Laine J, Kunstle G, Obata T, Sha M, Noguchi M. The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell 2000;6(2):395-407.
35. Cheson BD, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87(12):4990-4997.
36. Rossmann ED, Lewin N, Jeddi-Tehrani M, Österborg A, Mellstedt H. Intracellular T cell cytokines in patients with B cell chronic lymphocytic leukaemia (B-CLL). Eur J Haematol 2002;68(5):299-306.
37. Boyum A. Separation of lymphocytes, lymphocyte subgroups and monocytes: a review. Lymphology 1977;10(2):71-76.
38. Caligaris-Cappio F. Role of the microenvironment in chronic lymphocytic leukaemia. Br J Haematol 2003;123(3):380-388.
39. Serrano D, et al. Clonal expansion within the CD4+CD57+ and CD8+CD57+ T cell subsets in chronic lymphocytic leukemia. J Immunol 1997;158(3):1482-1489.
40. Rezvany MR, Jeddi-Tehrani M, Wigzell H, Österborg A, Mellstedt H. Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia. Blood 2003;101(3):1063-1070.
41. Kono K, et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell- and natural killer cell-mediated cytotoxicity. Eur J Immunol 1996;26(6):1308-1313.
42. Carbone JE, Ohm DP. Immune dysfunction in cancer patients. Oncology (Huntingt) 2002;16(1 Suppl 1):11-18.
43. Elgert KD, Alleva DG, Mullins DW. Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 1998;64(3):275-290.
44. Elflein K, Rodriguez-Palmero M, Kerkau T, Hunig T. Rapid recovery from T lymphopenia by CD28 superagonist therapy. Blood 2003;102(5):1764-1770.